Montadiol (Estradiol Hemihydrate)

Estradiol hemihydrate acts as an agonist at estrogen receptors in vaginal and uterine tissues. By binding these receptors, it triggers gene transcription that restores the thickness and elasticity of the vaginal epithelium, improves lubrication, and supports normal urinary tract function.

The specific dose and dosing schedule of Montadiol are determined by the prescribing clinician based on the individual’s condition, severity of symptoms, and overall health status. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Montadiol is generally contraindicated during pregnancy because systemic estrogen exposure can affect fetal development. Use while breastfeeding is only considered if the potential benefit justifies any possible risk to the infant, and this decision should be made by a healthcare professional.

To request Montadiol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Montadiol contains estradiol hemihydrate, a potent natural estrogen, similar to other vaginal estradiol formulations. Compared with conjugated estrogen or estriol preparations, estradiol provides a more direct replacement of the primary estrogen lost at menopause, often resulting in faster symptom relief, though individual response may vary.

Montadiol should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain its stability.

Montadiol is applied intravaginally using the supplied applicator or as directed by the prescriber. The patient inserts the product into the vagina, typically once daily for an initial period, followed by a maintenance schedule that the clinician determines based on therapeutic response.

Serious risks, although rare, include endometrial hyperplasia or carcinoma, venous thromboembolism (deep‑vein thrombosis, pulmonary embolism), stroke, myocardial infarction, severe allergic reactions, and hepatotoxicity. Patients should report any abnormal uterine bleeding, chest pain, shortness of breath, or signs of an allergic reaction immediately.

Montadiol is not recommended for women with a history of estrogen‑dependent cancers (such as breast or endometrial cancer), active or past thromboembolic disease, uncontrolled hypertension, liver disease, or known hypersensitivity to estradiol or any excipients in the formulation. A healthcare professional should evaluate suitability before prescribing.